$0.98
8.19% today
Nasdaq, Dec 04, 10:03 pm CET
ISIN
CA6823108759
Symbol
ONCY

Oncolytics Biotech Inc. Stock price

$0.98
+0.02 1.64% 1M
+0.64 188.53% 6M
+0.07 7.32% YTD
+0.10 11.19% 1Y
-0.95 49.19% 3Y
-3.05 75.67% 5Y
-2.06 67.74% 10Y
-44.90 97.86% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.07 8.19%
ISIN
CA6823108759
Symbol
ONCY
Industry

Key metrics

Basic
Market capitalization
$97.3m
Enterprise Value
$86.7m
Net debt
positive
Cash
$11.2m
Shares outstanding
97.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
22.3
Financial Health
Equity Ratio
29.6%
Return on Equity
-530.0%
ROCE
-231.3%
ROIC
-1,551.2%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-22.0m | $-45.0m
EBIT
$-22.2m | $-30.6m
Net Income
$-21.8m | $-22.3m
Free Cash Flow
$-17.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
15.1% | -81.5%
EBIT
15.1% | -22.1%
Net Income
-8.5% | 1.8%
Free Cash Flow
7.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
3.2%
Employees
28
Rev per Employee
$0.0
Show more

Is Oncolytics Biotech Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Oncolytics Biotech Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Oncolytics Biotech Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Oncolytics Biotech Inc. forecast:

Buy
75%
Hold
25%

Financial data from Oncolytics Biotech Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.89 8.89
19% 19%
-
- Research and Development Expense 13 13
12% 12%
-
-22 -22
15% 15%
-
- Depreciation and Amortization 0.28 0.28
10% 10%
-
EBIT (Operating Income) EBIT -22 -22
15% 15%
-
Net Profit -22 -22
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Oncolytics Biotech Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oncolytics Biotech Inc. Stock News

Neutral
Business Wire
14 days ago
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special meeting of shareholders (the “Special Meeting”), as described in its news release dated October 20, 2025, which was to be held on December 15, 2025. The Special Mee...
Neutral
Business Wire
15 days ago
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration (“FDA”) regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic du...
Neutral
PRNewsWire
about one month ago
Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was 15.5 months compared to 9.5 months for the current standard of care Company expects to discuss single-arm accelerated approval study with FDA in Q1 2026 SAN DIEGO, Calif. , Oct. 28, 2025 /PRNewswir...
More Oncolytics Biotech Inc. News

Company Profile

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Head office Canada
CEO Wayne Pisano
Employees 28
Founded 1998
Website www.oncolyticsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today